Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Inhibitory neurotransmission in the brain is largely mediated by GABA(A) receptors. Potentiation of GABA receptor activation through an allosteric benzodiazepine (BZ) site produces the sedative, anxiolytic, muscle relaxant, anticonvulsant and cognition-impairing effects of clinically used BZs such as diazepam. We created genetically modified mice (alpha1 H101R) with a diazepam-insensitive alpha1 subtype and a selective BZ site ligand, L-838,417, to explore GABA(A) receptor subtypes mediating specific physiological effects. These two complimentary approaches revealed that the alpha1 subtype mediated the sedative, but not the anxiolytic effects of benzodiazepines. This finding suggests ways to improve anxiolytics and to develop drugs for other neurological disorders based on their specificity for GABA(A) receptor subtypes in distinct neuronal circuits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, α 1-containing GABAA receptors probably mediate the sedative, amnesic, and anticonvulsant actions of classical benzodiazepines [13, 23].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [23]
Citations
Cites
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Wisden, W., Laurie, D., Monyer, H., & Seeburg, P. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-03-01040.1992 · Cited by 1,543
Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Fritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
Barnard, E. A., Skolnick, P., Olsen, R. W., Möhler, H., Sieghart, W., Biggio, G., Bræstrup, C., Bateson, A. N., & Langer, S. Z. (1998) · PubMed · Cited by 1,204
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Essential functions of synapsins I and II in synaptic vesicle regulation
Rosahl, T. W., Spillane, D., Missler, M., Herz, J., Selig, D. K., Wolff, J. R., Hammer, R. E., Malenka, R. C., & Südhof, T. C. (1995) · Nature · doi:10.1038/375488a0 · Cited by 719
Self-citationType I and Type II GABA A -Benzodiazepine Receptors Produced in Transfected Cells
Pritchett, D. B., Lüddens, H., & Seeburg, P. H. (1989) · Science · doi:10.1126/science.2551039 · Cited by 717
Laurie, D., Seeburg, P., & Wisden, W. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-03-01063.1992 · Cited by 667
Research works printed but not linked: 2
- Barnard, E. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50, 291–313 (1998).
- Sieghart, W. Structure and function of γ-aminobutyric acidA receptor subtypes. Pharmacol. Rev. 47, 181–234 (1995).
Cited by
Items 101–200 of 1,000
Young, G. T., Gutteridge, A., Fox, H. D., Wilbrey, A. L., Cao, L., Cho, L. T., Brown, A. R., Benn, C. L., Kammonen, L. R., Friedman, J. H., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.86 · Cited by 148
Self-citationGABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?
Wafford, K. A. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.006 · Cited by 156
Self-citationCriteria for validating mouse models of psychiatric diseases
Chadman, K. K., Yang, M., & Crawley, J. N. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30777 · Cited by 122
GABAA receptor subtypes as targets for neuropsychiatric drug development
Korpi, E. R., & Sinkkonen, S. T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.009 · Cited by 149
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Anxiogenic properties of an inverse agonist selective for α 3 subunit‐containing GABAA receptors
Atack, J. R., Hutson, P. H., Collinson, N., Marshall, G., Bentley, G., Moyes, C., Cook, S. M., Collins, I., Wafford, K., McKernan, R. M., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706056 · Cited by 134
Self-citationSpecific GABAA circuits in brain development and therapy
Möhler, H., Fritschy, J., Crestani, F., Hensch, T. K., & Rudolph, U. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.025 · Cited by 146
Carling, R. W., Moore, K. W., Street, L. J., Wild, D., Isted, C., Leeson, P. D., Thomas, S., O'Connor, D. V., McKernan, R. M., Quirk, K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031020p · Cited by 146
Self-citationBenzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective
Goldschen-Ohm, M. P. (2022) · Biomolecules · doi:10.3390/biom12121784 · Cited by 146
van Rijnsoever, C., Täuber, M., Choulli, M. K., Keist, R., Rudolph, U., Mohler, H., Fritschy, J. M., & Crestani, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1067-04.2004 · Cited by 144
Goodacre, S. C., Street, L. J., Hallett, D. J., Crawforth, J. M., Kelly, S., Owens, A. P., Blackaby, W., Lewis, R. T., Stanley, J. L., Smith, A. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm051065l · Cited by 144
Self-citationBonne, O. B., Grillon, C., Vythilingam, M., Neumeister, A., & Charney, D. S. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.12.001 · Cited by 146
Modulation of rhythmic brain activity by diazepam: GABA A receptor subtype and state specificity
Kopp, C., Rudolph, U., Löw, K., & Tobler, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306975101 · Cited by 133
GABA-A receptors: a viable target for novel anxiolytics?
Whiting, P. J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.08.005 · Cited by 142
Self-citationGABA receptors, progesterone and premenstrual dysphoric disorder
Poromaa, I. S., Smith, S. S., & Gulinello, M. E. (2003) · Archives of Women s Mental Health · doi:10.1007/s00737-002-0147-1 · Cited by 144
Flavonoids as GABAA receptor ligands: the whole story?
Marder, M. (2012) · Journal of Experimental Pharmacology · doi:10.2147/jep.s23105 · Cited by 141
Target site occupancy: Emerging generalizations from clinical and preclinical studies
Grimwood, S., & Hartig, P. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.002 · Cited by 139
Neonatal development of the rat visual cortex: synaptic function of GABAa receptor α subunits
Bosman, L. W. J., Rosahl, T. W., & Brussaard, A. B. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2002.026534 · Cited by 126
Self-citationde Almeida, R. M. M., Cabral, J. C. C., & Narvaes, R. F. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.02.053 · Cited by 144
Baude, A., Bleasdale, C., Dalezios, Y., Somogyi, P., & Klausberger, T. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhl117 · Cited by 137
Sankar, R. (2011) · CNS Drugs · doi:10.2165/11599020-000000000-00000 · Cited by 137
LEWIS, D. A., CRUZ, D., EGGAN, S., & ERICKSON, S. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1308.008 · Cited by 122
Engin, E., Liu, J., & Rudolph, U. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.006 · Cited by 129
Selective anxiolysis produced by ocinaplon, a GABA A receptor modulator
Lippa, A., Czobor, P., Stark, J., Beer, B., Kostakis, E., Gravielle, M., Bandyopadhyay, S., Russek, S. J., Gibbs, T. T., Farb, D. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502579102 · Cited by 125
The Genes and Brains of Mice and Men
Tecott, L. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.646 · Cited by 115
Locci, A., & Pinna, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13843 · Cited by 132
A Unified Model of the GABAA Receptor Comprising Agonist and Benzodiazepine Binding Sites
Bergmann, R., Kongsbak, K., Sørensen, P. L., Sander, T., & Balle, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052323 · Cited by 132
GABAA-receptor subtypes: a new pharmacology
Möhler, H., Crestani, F., & Rudolph, U. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00008-x · Cited by 131
Therapeutic Options for Sleep‐Maintenance and Sleep‐Onset Insomnia
Morin, A. K., Jarvis, C. I., & Lynch, A. M. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.1.89 · Cited by 122
SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats
Knapp, D. J., Overstreet, D. H., Moy, S. S., & Breese, G. R. (2004) · Alcohol · doi:10.1016/j.alcohol.2003.08.007 · Cited by 130
“With regard to GABAA receptors, zolpidem preferentially binds to α1 GABA subunit–containing receptors (benzodiazepine type 1 receptors) (Doble, 1999; Mereu et al., 1990), an effect that may bias zolpidem’s behavioral actions toward sedation rather than anxiolysis (McKernan et al., 2000).”
BackgroundAli, A. B., & Thomson, A. M. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm160 · Cited by 129
GABAergic analgesia: new insights from mutant mice and subtype-selective agonists
Zeilhofer, H. U., Möhler, H., & Lio, A. D. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.007 · Cited by 130
Humphries, A. C., Gancia, E., Gilligan, M. T., Goodacre, S. C., Hallett, D. J., Merchant, K. J., & Thomas, S. R. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.037 · Cited by 128
Petroski, R. E., Pomeroy, J. E., Das, R., Bowman, H., Yang, W., Chen, A. P., & Foster, A. C. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096701 · Cited by 128
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Smith, K. S., & Rudolph, U. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.026 · Cited by 114
Perucca, E., Bialer, M., & White, H. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01027-2 · Cited by 127
Chambers, M. S., Atack, J. R., Carling, R. W., Collinson, N., Cook, S. M., Dawson, G. R., Ferris, P., Hobbs, S. C., O'Connor, D., Marshall, G., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040863t · Cited by 109
Self-citationPetrache, A. L., Rajulawalla, A., Shi, A., Wetzel, A., Saito, T., Saido, T. C., Harvey, K., & Ali, A. B. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz016 · Cited by 124
“2007), which are subtypes of GABAA receptors shown to be associated with postsynaptic domains targeted by PV interneurons (Ali and Thomson 2008), and with little sedative or amnestic effects that are associated with α1 subtypes (McKernan et al. 2000).”
BackgroundHow do general anaesthetics work?
Antkowiak, B. (2001) · Die Naturwissenschaften · doi:10.1007/s001140100230 · Cited by 124
Anticonvulsant effect of wogonin isolated from Scutellaria baicalensis
Park, H. G., Yoon, S. Y., Choi, J. Y., Lee, G. S., Choi, J. H., Shin, C. Y., Son, K. H., Lee, Y. S., Kim, W. K., Ryu, J. H., et al. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.011 · Cited by 122
Selective, Orally Active γ-Aminobutyric Acid A α5 Receptor Inverse Agonists as Cognition Enhancers
Sternfeld, F., Carling, R. W., Jelley, R. A., Ladduwahetty, T., Merchant, K. J., Moore, K. W., Reeve, A. J., Street, L. J., O'Connor, D., Sohal, B., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031076j · Cited by 104
Self-citationCollins, I., Moyes, C., Davey, W. B., Rowley, M., Bromidge, F. A., Quirk, K., Atack, J. R., McKernan, R. M., Thompson, S.-A., Wafford, K., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0110789 · Cited by 109
Self-citationFrom synapse to behavior: rapid modulation of defined neuronal types with engineered GABAA receptors
Wulff, P., Goetz, T., Leppä, E., Linden, A.-M., Renzi, M., Swinny, J. D., Vekovischeva, O. Y., Sieghart, W., Somogyi, P., Korpi, E. R., et al. (2007) · Nature Neuroscience · doi:10.1038/nn1927 · Cited by 110
Gulinello, M. E., Gong, Q. H., & Smith, S. S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00171-5 · Cited by 120
Lingford-Hughes, A., Hume, S. P., Feeney, A., Hirani, E., Osman, S., Cunningham, V. J., Pike, V. W., Brooks, D. J., & Nutt, D. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200207000-00013 · Cited by 112
The rise of a new GABA pharmacology
Möhler, H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.020 · Cited by 120
GABAAReceptor α5 Subunits Contribute to GABAA,slowSynaptic Inhibition in Mouse Hippocampus
Zarnowska, E. D., Keist, R., Rudolph, U., & Pearce, R. A. (2009) · Journal of Neurophysiology · doi:10.1152/jn.91203.2008 · Cited by 104
Functional mapping of GABAA receptor subtypes in the amygdala
Marowsky, A., Fritschy, J., & Vogt, K. E. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03574.x · Cited by 107
Ralvenius, W. T., Benke, D., Acuña, M. A., Rudolph, U., & Zeilhofer, H. U. (2015) · Nature Communications · doi:10.1038/ncomms7803 · Cited by 105
Morris, H. V., Dawson, G. R., Reynolds, D. S., Atack, J. R., & Stephens, D. N. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04775.x · Cited by 110
Self-citationIon Channels as Drug Targets in Central Nervous System Disorders
Waszkielewicz, A. M., Gunia‐Krzyżak, A., Szkaradek, N., Słoczyńska, K., Krupinska, S., & Marona, H. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320100005 · Cited by 118
Hippocampal α5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition
Hauser, J., Rudolph, U., Keist, R., Möhler, H., Feldon, J., & Yee, B. K. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001554 · Cited by 116
Kwakowsky, A., Calvo‐Flores Guzmán, B., Pandya, M., Turner, C., Waldvogel, H. J., & Faull, R. L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14325 · Cited by 95
Principles of Antiepileptic Drug Action
Rogawski, M. A. (2002) · Cited by 115
A novel GABAAreceptor pharmacology: drugs interacting with the α+β‐interface
Sieghart, W., Ramerstorfer, J., Sarto‐Jackson, I., Varagić, Z., & Ernst, M. C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01779.x · Cited by 112
Anxioselective anxiolytics: on a quest for the Holy Grail
Skolnick, P. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.08.003 · Cited by 105
GABAA receptor modulation by terpenoids from Sideritis extracts
Kessler, A., Nadeem, H. Ş., Lummis, S. C. R., Weigel, I., Pischetsrieder, M., Buettner, A., & Villmann, C. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300420 · Cited by 110
Anesthetic sites and allosteric mechanisms of action on Cys-loop ligand-gated ion channels
Forman, S. A., & Miller, K. W. (2011) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-010-9419-9 · Cited by 104
Ng, Y., & Collins, S. D. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.002 · Cited by 110
Current status of GABA receptor subtypes in analgesia
Qian, X., Zhao, X., Yu, L., Yin, Y., Zhang, X., Wang, L., Li, J., Zhu, Q., & Luo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115800 · Cited by 109
Tolerance to allopregnanolone with focus on the GABA‐A receptor
Turkmen, S., Backstrom, T., Wahlstrom, G., Andreen, L., & Johansson, I. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01059.x · Cited by 97
Evans, A. K., & Lowry, C. A. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00025.x · Cited by 96
Cagetti, E., Pinna, G., Guidotti, A., Baicy, K., & Olsen, R. W. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.001 · Cited by 107
Modulation of Ionotropic GABA Receptors by Natural Products of Plant Origin
Johnston, G. A. R., Hanrahan, J. R., Chebib, M., Duke, R. K., & Mewett, K. N. (2006) · Advances in pharmacology · doi:10.1016/s1054-3589(06)54012-8 · Cited by 106
Collinson, N., Atack, J. R., Laughton, P., Dawson, G. R., & Stephens, D. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0361-z · Cited by 108
Self-citationGABA Receptors and the Pharmacology of Sleep
Wisden, W., Yu, X., & Franks, N. P. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_56 · Cited by 105
The fallacy of behavioral phenotyping without standardisation
Van Der Staay, F. J., & Steckler, T. (2002) · Genes, Brain and Behavior · doi:10.1046/j.1601-1848.2001.00007.x · Cited by 100
de Haas, S. L., de Visser, S. J., van der Post, J. P., Schoemaker, R. C., van Dyck, K., Murphy, M. G., de Smet, M., Vessey, L. K., Ramakrishnan, R., Xue, L., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082108 · Cited by 104
Shisa7 is a GABA A receptor auxiliary subunit controlling benzodiazepine actions
Han, W., Li, J., Pelkey, K. A., Pandey, S., Chen, X., Wang, Y.-X., Wu, K., Ge, L., Li, T., Castellano, D., et al. (2019) · Science · doi:10.1126/science.aax5719 · Cited by 95
An Historical Perspective on Gabaergic Drugs
Froestl, W. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.10.285 · Cited by 103
The 5-HT 1A receptor knockout mouse and anxiety
Olivier, B., Pattij, T., Wood, S. J., Oosting, R., Sarnyai, Z., & Toth, M. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200111000-00004 · Cited by 89
GABAA receptor subtype involvement in addictive behaviour
Stephens, D. N., King, S. L., Lambert, J. J., Belelli, D., & Duka, T. (2016) · Genes Brain & Behavior · doi:10.1111/gbb.12321 · Cited by 101
The benzodiazepine site of the GABA receptor: an old target with new potential?
Bateson, A. N. (2004) · Sleep Medicine · doi:10.1016/s1389-9457(04)90002-0 · Cited by 100
Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles
Prevot, T. D., Li, G., Vidojevic, A., Misquitta, K. A., Fee, C., Santrac, A., Knutson, D. E., Stephen, M. R., Kodali, R., Zahn, N. M., et al. (2019) · Complex Psychiatry · doi:10.1159/000496086 · Cited by 86
The Role of Benzodiazepines in the Treatment of Epilepsy
Ochoa, J. G., & Kilgo, W. A. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0401-x · Cited by 99
Lio, A. D., Benke, D., Besson, M. J., Desmeules, J. A., Daali, Y., Wang, Z., Edwankar, R. V., Cook, J. M., & Zeilhofer, H. U. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.11.026 · Cited by 98
Manayi, A., Nabavi, S. M., Daglia, M., & Jafari, S. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.014 · Cited by 98
Engin, E., & Treit, D. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.020 · Cited by 98
The Reinforcing Properties of Alcohol are Mediated by GABAA1 Receptors in the Ventral Pallidum
June, H. L., Foster, K. L., McKay, P. F., Seyoum, R., Woods, J. E., Harvey, S. C., Eiler, W. J. A., Grey, C., Carroll, M. R., McCane, S., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300239 · Cited by 97
Unraveling the function of GABAA receptor subtypes
Sieghart, W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01564-9 · Cited by 95
Smith, K. S., Engin, E., Meloni, E. G., & Rudolph, U. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.001 · Cited by 94
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 97
Olsen, R. W. (2015) · Advances in pharmacology · doi:10.1016/bs.apha.2014.11.005 · Cited by 93
Enhancing neuronal chloride extrusion rescues α2/α3 GABAA-mediated analgesia in neuropathic pain
Lorenzo, L.-É., Godin, A. G., Ferrini, F., Bachand, K., Plasencia-Fernández, I., Labrecque, S., Girard, A. A., Boudreau, D., Kianicka, I., Gagnon, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14154-6 · Cited by 93
Goldstein, P. A., Elsen, F. P., Ying, S.-W., Ferguson, C., Homanics, G. E., & Harrison, N. L. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00885.2001 · Cited by 86
Izzo, E., Auta, J., Impagnatiello, F., Pesold, C., Guidotti, A., & Costa, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628698 · Cited by 90
The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review
Philip, A. B., Brohan, J., & Goudra, B. (2024) · CNS Drugs · doi:10.1007/s40263-024-01128-6 · Cited by 92
Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors
Smith, S. G., Sanchez, R., & Zhou, M.-M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.03.004 · Cited by 81
GABA signalling: therapeutic targets for epilepsy, Parkinson’s disease and Huntington’s disease
Kleppner, S. R., & Tobin, A. J. (2001) · Emerging Therapeutic Targets · doi:10.1517/14728222.5.2.219 · Cited by 89
Animal Models of Anxiety and Anxiolytic Drug Action
Treit, D., Engin, E., & McEown, K. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_17 · Cited by 89
Benzodiazepine Augmented γ-Amino-Butyric Acid Signaling Increases Mortality From Pneumonia in Mice*
Sanders, R. D., Godlee, A., Fujimori, T., Goulding, J., Xin, G., Salek-Ardakani, S., Snelgrove, R. J., Ma, D., Maze, M., & Hussell, T. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827c0c8d · Cited by 81
Mirza, N. R., Larsen, J. S., Mathiasen, C., Jacobsen, T. A., Munro, G., Erichsen, H. K., Nielsen, A. N., Troelsen, K. B., NIELSEN, E. O., & Ahring, P. K. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138859 · Cited by 90
The pyridazine heterocycle in molecular recognition and drug discovery
Meanwell, N. A. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03035-9 · Cited by 88
Peden, D. R., Petitjean, C. M., Herd, M. B., Durakoglugil, M. S., Rosahl, T. W., Wafford, K., Homanics, G. E., Belelli, D., Fritschy, J., & Lambert, J. J. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2007.145375 · Cited by 81
Self-citationFollesa, P., Concas, A., Porcu, P., Sanna, E., Serra, M., Mostallino, M. C., Purdy, R. H., & Biggio, G. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00125-4 · Cited by 90
Maramai, S., Benchekroun, M., Ward, S. E., & Atack, J. R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01312 · Cited by 87
Self-citationTowers, S. K., Gloveli, T., Traub, R. D., Driver, J. E., Engel, D., Fradley, R., Rosahl, T. W., Maubach, K., Buhl, E. H., & Whittington, M. A. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.071191 · Cited by 76
Self-citationWu, L.-J., Ko, S. W., Toyoda, H., Zhao, M.-G., Xu, H., Vadakkan, K. I., Ren, M., Knifed, E., Shum, F., Quan, J., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000167 · Cited by 82
Silva, M. I. G., Silva, M. A. G., Neto, M. R. D. A., Moura, B. A., de Sousa, H. L., de Lavor, E. P. H., de Vasconcelos, P. F., Macêdo, D. S., de Sousa, D. P., Vasconcelos, S. M. M., et al. (2009) · Fitoterapia · doi:10.1016/j.fitote.2009.06.011 · Cited by 86
Metadata
- Authors
- McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., Garrett, L., Bristow, L., Marshall, G., Macaulay, A., Brown, N., Howell, O., Moore, K. W., Carling, R. W., Street, L. J., Castro, J. L., Ragan, C. I., Dawson, G. R., & Whiting, P. J.
- Affiliations
- MSD (UK) Limited (United Kingdom) (GB)
- Corresponding author
- McKernan, R. M.
- ORCID
- Venue
- Nature Neuroscience
- Published
- 2000-06
- Volume
- 3
- Issue
- 6
- Pages
- 587-592
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2001619275
- Cited by
- 944
- References
- 35
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 23 · 2022: 14 · 2021: 23 · 2020: 30 · 2019: 24 · 2018: 37 · 2017: 22 · 2016: 30 · 2015: 29 · 2014: 32 · 2013: 36 · 2012: 37
- FWCI
- 19.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Keywords
- benzodiazepines, GABAA receptor, alpha1 subunit, sedation, anxiolytic effects, genetically modified mice, inhibitory neurotransmission, diazepam
- MeSH terms
- Allosteric Site, Animals, Anticonvulsants, Azides, Benzodiazepines, Binding, Competitive, Brain, Cell Line, Diazepam, Dose-Response Relationship, Drug, Flumazenil, Fluorobenzenes, Hypnotics and Sedatives, Ligands, Mice, Inbred C57BL, Mice, Mutant Strains, Motor Activity, Receptors, GABA-A, Reflex, Startle, Anti-Anxiety Agents, Triazoles, Patch-Clamp Techniques, Mice, GABA-A Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.